Skip Navigation

Publications & Presentations

Adoptive transfer of T cells surface-tethered with IL-12 promotes antigen spreading for enhanced anti-tumor efficacy

Download

PRIME™ IL-15 (RPTR-147): Preliminary clinical results and biomarker analysis from a first-in-human Phase 1 study of IL-15 loaded peripherally-derived autologous T cell therapy in solid tumor patients

Download

Deep TLR Primed™ T cells induce potent anti-tumor activity without systemic toxicity.

Download

Combining Deep IL-12 Primed™ and Deep IL-15 Primed™ T cells induces potent antigen-dependent in vitro cytotoxicity and in vivo anti-tumor activity.

Download

Adoptive transfer of deep primed™ IL-12 T-cells increases sensitivity to PD-L1 blockade for superior efficacy in checkpoint refractory tumors.

Download

Delivery of TLR7 agonists by Deep-Primed™ T cells induces immune activation and improves anti-tumor activity in mice while circumventing systemic toxicity.

Download

Optimized process for manufacturing Deep-Primed™ T cells creates product with improved functional characteristics and reactivity against multiple tumor-associated antigens.

Download

Deep IL-15 primed T cells synergize with PD-L1 blockade to overcome resistance to checkpoint immunotherapy.

Download

Deep™ IL-15 Primed multi-targeted T cells demonstrate potent antigen-specific cytotoxic activity against human cancer cells.

Download

Surface-tethered IL-12 improves tumor-specific T-cell therapy and enhances inflammatory activity in tumors without inducing systemic toxicities.

Download

Tethering IL-12 to the surface of T cells induces broad immune activation and potent anti-tumor activity in mice without inducing systemic toxicities.

Download

Preclinical evaluation of Deep™ IL-15 Primed PMEL cells demonstrates highly improved safety compared to systemic administration of IL-15.

Download

A fully closed, high efficiency manufacturing technology platform for the production of T cell therapies targeting multiple tumor antigens.

Download

T cell priming with Deep™ IL-15 improves preclinical safety compared to systemic IL-15, and increases in vivo persistence and activity.

Download

Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery.

Download

Deep™ IL-15 provides autocrine stimulation and expansion of autologous T cells driven by controlled concentrated release of IL-15.

Download

Cell therapy with surface-tethered IL-12 provides immune system priming and strong anti-tumor activity.

Download

T cell receptor signaling-responsive single chain IL-12 and IL-15 superagonist nanogel ‘backpacks’ to enhance adoptive cell therapy in solid tumors.

Download

Antigen recognition-triggered drug delivery mediated by nanocapsule-functionalized cytotoxic T-cells.

Download

Synapse-directed delivery of immunomodulators using T-cell-conjugated nanoparticles.

Download

Therapeutic cell engineering with surface-conjugated synthetic nanoparticles.

Download